Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

PHASE2RecruitingINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

August 1, 2024

Study Completion Date

November 1, 2029

Conditions
Bladder CancerBladder Cancer, Metastatic
Interventions
DRUG

Atezolizumab

The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.

Trial Locations (5)

2100

RECRUITING

Rigshospitalet, Copenhagen

2730

RECRUITING

Herlev Hospital, Herlev

5000

RECRUITING

Odense Universitetshospital, Odense

8200

RECRUITING

Aarhus University Hospital, Aarhus

9100

RECRUITING

Aalborg Universitetshospital, Aalborg

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

collaborator

Herlev Hospital

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Aalborg University Hospital

OTHER

lead

Jørgen Bjerggaard Jensen

OTHER

NCT04138628 - Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy | Biotech Hunter | Biotech Hunter